He Xu-Dong, Li Min, Zuo Xiang-Duo, Ni Hao-Yu, Han Yu-Xin, Hu Yun-Kai, Yu Jie, Yang Xing-Xin
College of Pharmaceutical Science, Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China.
Yunnan Key Laboratory of Integrated Traditional Chinese and Western Medicine for Chronic Disease in Prevention and Treatment, Yunnan University of Chinese Medicine, Kunming 650500, Yunnan Province, China.
World J Gastroenterol. 2025 Jul 14;31(26):105656. doi: 10.3748/wjg.v31.i26.105656.
Kushenol I (KSCI) exhibits potential anti-inflammatory and antioxidant activities. However, its therapeutic effects and mechanisms in ulcerative colitis (UC) remain unclear.
To investigate the therapeutic effects and mechanisms of KSCI in alleviating UC.
Therapeutic targets for KSCI in treating UC were identified using network pharmacology. Molecular docking and dynamics simulations confirmed the interactions between KSCI and these targets. In a murine UC model induced by dextran sodium sulfate (DSS), the anti-inflammatory and antioxidant effects of KSCI were evaluated following oral administration, as well as its impact on intestinal barrier function and immune response modulation. Finally, changes in gut microbiota composition were analyzed using 16S ribosomal RNA sequencing.
A total of 192 potential targets of KSCI in treating UC were identified using network pharmacology. KSCI bound stably to core targets including protein kinase B (AKT), p38 mitogen-activated protein kinase (p38 MAPK), NOD-like receptor thermal protein domain associated protein 3 (NLRP3), phosphoinositide 3-kinase (PI3K), forkhead box O1 (FOXO1), and Toll-like receptor 4 (TLR4). The oral administration of KSCI improved colon length and body weight, and reduced disease activity in a mouse model of DSS-induced UC. KSCI suppressed pro-inflammatory cytokines (interleukin [IL-1β], IL-6, IL-17, and tumor necrosis factor alpha) and promoted the expression of the anti-inflammatory cytokine IL-10. It also inhibited key signaling molecules and modulated the expression of IL-1β, AKT, p38 MAPK, NLRP3, PI3K, AKT, FOXO1, and TLR4. KSCI exhibited potent antioxidant effects, ameliorating colonic inflammation and tissue damage. It improved intestinal barrier function, influenced gut microbiota composition, and increased splenic T-cell percentages.
KSCI alleviated DSS-induced UC by modulating gut microbiota, enhancing the intestinal barrier, reducing inflammation and oxidative stress, and regulating the immune response.
苦参醇I(KSCI)具有潜在的抗炎和抗氧化活性。然而,其在溃疡性结肠炎(UC)中的治疗作用和机制仍不清楚。
研究KSCI缓解UC的治疗作用和机制。
采用网络药理学确定KSCI治疗UC的靶点。分子对接和动力学模拟证实了KSCI与这些靶点之间的相互作用。在葡聚糖硫酸钠(DSS)诱导的小鼠UC模型中,口服给药后评估KSCI的抗炎和抗氧化作用,以及其对肠道屏障功能和免疫反应调节的影响。最后,使用16S核糖体RNA测序分析肠道微生物群组成的变化。
通过网络药理学共确定了KSCI治疗UC的192个潜在靶点。KSCI与包括蛋白激酶B(AKT)、p38丝裂原活化蛋白激酶(p38 MAPK)、NOD样受体热蛋白结构域相关蛋白3(NLRP3)、磷脂酰肌醇3激酶(PI3K)、叉头框O1(FOXO1)和Toll样受体4(TLR4)在内的核心靶点稳定结合。口服KSCI可改善DSS诱导的UC小鼠模型的结肠长度和体重,并降低疾病活动度。KSCI抑制促炎细胞因子(白细胞介素[IL-1β]、IL-6、IL-17和肿瘤坏死因子α),并促进抗炎细胞因子IL-10的表达。它还抑制关键信号分子,并调节IL-1β、AKT、p38 MAPK、NLRP3、PI3K、AKT、FOXO1和TLR4的表达。KSCI表现出强大的抗氧化作用,减轻结肠炎症和组织损伤。它改善肠道屏障功能,影响肠道微生物群组成,并增加脾脏T细胞百分比。
KSCI通过调节肠道微生物群、增强肠道屏障、减轻炎症和氧化应激以及调节免疫反应来缓解DSS诱导的UC。